Thomas Eschenhagen - Toxicology

Author Information

Thomas Eschenhagen is a prominent researcher associated with the Department of Experimental Pharmacology and Toxicology at the University Medical Center Hamburg-Eppendorf. In addition to his primary affiliation, he is also connected with the Cardiovascular Research Center Hamburg and the German Centre for Cardiovascular Research (DZHK) at the partner site in Hamburg/Kiel/Lübeck. His research spans across several domains within pharmacology and toxicology, with a significant focus on cardiovascular research.

Research Contributions

Thomas Eschenhagen has made substantial contributions to the field of cardiovascular research and toxicology. His recent work includes studies on human induced pluripotent stem cells, engineered heart tissues, and cardiac differentiation. In 2022 alone, he has published numerous papers exploring topics such as oxygen concentration effects on stem cells, potential treatments for univentricular heart defects, and the metabolic maturation of stem-cell-derived cardiomyocytes. His research often employs advanced techniques like proteomic analysis and engineered tissue models, emphasizing innovation in treatment strategies for cardiac conditions.

Aliases

Thomas Eschenhagen is known by several variations of his name in academic publications, including "T Eschenhagen" and "T. Eschenhagen." Despite these variations, his work is consistently recognized under these aliases in scientific communities.

Publication and Citation Metrics

Metric	Value
Total Citation Count	26,336
h-index	87
Total Paper Count	578

Publications:

Comparison of Human Induced Pluripotent Stem Cells Cultured at Different Oxygen Concentrations by Proteomic Analysis Suggests Normoxia-induced Cellular Senescence

DOI: 10.1016/j.freeradbiomed.2021.12.047

Year: 2022

A potential future Fontan modification: preliminary in vitro data of a pressure-generating tube from engineered heart tissue.

DOI: 10.1093/ejcts/ezac111

Year: 2022

Muscarinic receptor activation reduces force and arrhythmias in human atria independent of IK,ACh.

DOI: 10.1097/FJC.0000000000001237

Year: 2022

Human engineered heart tissue transplantation in a guinea pig chronic injury model.

DOI: 10.1016/j.yjmcc.2022.01.007

Year: 2022

SERCA2a gain of function in patient-derived R14Del hiPSC-CMs.

DOI: 10.1085/jgp.2021ecc3

Year: 2022

Development of a Subpulmonary Neoventricle from Engineered Heart Tissue for the Treatment of Univentricular Heart Defects

DOI: 10.1055/s-0042-1742900

Year: 2022

PPARdelta activation induces metabolic and contractile maturation of human pluripotent stem-cell-derived cardiomyocytes.

DOI: 10.1016/j.stem.2022.02.011

Year: 2022

Age-Dependent Increase in AF Cannot Be Explained by Shortening of Action Potential Duration

DOI: 10.2139/ssrn.4065592

Year: 2022

The mutation R400Q in mitofusin 2 impairs in vitro cardiac differentiation of human induced pluripotent stem cells and induces fibrosis in engineered heart tissues

DOI: 10.1016/j.freeradbiomed.2021.12.117

Year: 2022

Comprehensive analyses of the inotropic compound omecamtiv mecarbil in rat and human cardiac preparations.

DOI: 10.1152/ajpheart.00534.2021

Year: 2022

What are the Challenges in Targeting Viral Enzymes?

Are Iron Oxides Toxic?

How Does Pollution Monitoring Impact Public Health?

How is CINV Classified?

How Do We Assess the Risk of Mixtures?

How is the Data Utilized?

How is Ephedrine Controlled Internationally?

What is Entrez?

What Future Directions Could the UN Take in Toxicology?

What Factors Influence the Choice of Bacteriostatic Agents?

Partnered Content Networks

Relevant Topics